Vaxcyte Inc (FRA:5VA)
€ 70 0.5 (0.75%) Market Cap: 7.62 Bil Enterprise Value: 6.25 Bil PE Ratio: 0 PB Ratio: 4.11 GF Score: 42/100

Vaxcyte Inc at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript

Oct 05, 2021 / 03:30PM GMT
Release Date Price: €21.4 (-4.46%)
Seamus Fernandez
Guggenheim Securities - Analyst

So thanks, everybody, for joining us. And this is our 2nd Annual Vaccines and Infectious Diseases Day. We were joined last year by Vaxcyte, so I just want to thank the team for joining us again. Many of you know me, I'm Seamus Fernandez, Guggenheim's global pharma analyst. And with us again this year is Vaxcyte. Many of you know Vaxcyte is a vaccine company with a unique platform that enables the development of vaccines to prevent some of the most common infectious diseases. Their lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine to prevent invasive pneumococcal disease. Many of you know that this is a $6 billion-plus global market, so there is certainly a lot of interest and enthusiasm for this space. I'm going to hand it over to CEO and Founder, Grant Pickering, for opening remarks and introductions to the rest of the team with us today. So, Grant, over to you.

Grant Pickering
Vaxcyte, Inc. - CEO, Director & Founder

Thank you, Seamus. Let me just start by saying thank you very much for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot